(Total Views: 484)
Posted On: 09/24/2024 4:38:05 PM
Post# of 154302
I do think they will now shop this around to BP - at the very least to keep them informed of the MASH progress. They released these preliminary finding very soon after the study ended demonstrating management’s exuberance and confidence in LL in the MASH space.
Not only did they not hold back the early observations, they threw some shade at Resmiterom in Point #3 when they said, “Leronlimab monotherapy (700 mg) appears to have better anti-fibrotic activity compared to Resmetirom (p=0.057).”
They used the word “appears” because the p value is not less than 0.05, and they didn’t want to upset the FDA, but I think Ohm is right, that a larger mouse study would probably bring that p value to less than 0.05.
I loved points 1) and 2) but 3 gave me a confident chuckle
Not only did they not hold back the early observations, they threw some shade at Resmiterom in Point #3 when they said, “Leronlimab monotherapy (700 mg) appears to have better anti-fibrotic activity compared to Resmetirom (p=0.057).”
They used the word “appears” because the p value is not less than 0.05, and they didn’t want to upset the FDA, but I think Ohm is right, that a larger mouse study would probably bring that p value to less than 0.05.
I loved points 1) and 2) but 3 gave me a confident chuckle
(8)
(0)
